CROSSJECT (FRA:74C) Total Operating Expense: €1.86 Mil (TTM As of Dec. 2025)


FRA:74C CROSSJECT FRA:74C
41 GF Score
Price €1.66
GF Value €1.11
Valuation Significantly Overvalued
! 4 Warning Signs
View Full Analysis

What is CROSSJECT Total Operating Expense?

CROSSJECT FRA:74C +0.12% 41 Total Operating Expense is €1.86 Mil as of Dec. 2025. GuruFocus rates FRA:74C with a GF Score™ of 41/100 and a GF Value™ of €1.11 (Significantly Overvalued). The stock has 4 warning signs investors should review.

CROSSJECT's Total Operating Expense for the six months ended in Dec. 2025 was €1.27 Mil. CROSSJECT's Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 was €1.86 Mil.

CROSSJECT Total Operating Expense Related Terms

CROSSJECT Total Operating Expense Historical Data

* Premium members only.

The historical data trend for CROSSJECT's Total Operating Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

CROSSJECT Total Operating Expense Chart

CROSSJECT Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Total Operating Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 11.43 12.08 5.46 3.74 1.86

CROSSJECT Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Total Operating Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.95 2.94 0.81 0.60 1.27
FRA:74C
41GF Score
CROSSJECT FRA:74C
Total Operating Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

CROSSJECT Total Operating Expense Calculation

Total Operating Expense is the primary recurring expense associated with central operations that are incurred in order to generate sales.


Total Operating Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was €1.86 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

What does a Total Operating Expense of €1.86 Mil mean?
CROSSJECT (FRA:74C) has a Total Operating Expense of €1.86 Mil as of Dec. 2025. Total operating expense is the primary recurring expense associated with central operations. View historical data on CROSSJECT and its competitors.
Is CROSSJECT's Total Operating Expense too high?
CROSSJECT's current Total Operating Expense is €1.86 Mil. Overall, CROSSJECT has a GF Score™ of 41/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does CROSSJECT's Total Operating Expense compare to ISRG and BDX?
CROSSJECT's Total Operating Expense of €1.86 Mil can be compared against companies in the Medical Devices & Instruments industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Total Operating Expense for a Medical Devices & Instruments company?
A good Total Operating Expense depends on the Medical Devices & Instruments industry context. However, Total Operating Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Total Operating Expense mean?
A high Total Operating Expense can signal that a stock is expensive relative to its fundamentals. Total operating expense is the primary recurring expense associated with central operations. View historical data on CROSSJECT and its competitors. CROSSJECT's current Total Operating Expense is €1.86 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is CROSSJECT stock overvalued right now?
Based on GuruFocus' analysis, CROSSJECT (FRA:74C) is currently considered Significantly Overvalued. The stock's GF Value™ is €1.11, compared to a current price of €1.66 — trading 49.9% above its estimated fair value. The current Total Operating Expense is €1.86 Mil. CROSSJECT's overall GF Score™ is 41/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Total Operating Expense calculated?
Total Operating Expense is calculated from a company's financial statements. For CROSSJECT (FRA:74C), the current Total Operating Expense is €1.86 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Is CROSSJECT (FRA:74C) Overvalued in 2026?

Based on GuruFocus' analysis, CROSSJECT stock appears to be overvalued. The current stock price of €1.66 is trading 49.9% above its estimated GF Value™ of €1.11. GuruFocus considers CROSSJECT to be Significantly Overvalued.

Key valuation signals for FRA:74C:

  • Total Operating Expense: €1.86 Mil
  • GF Value™: €1.11 vs. price of €1.66 (49.9% above fair value)
  • GF Score™: 41/100 with 4 warning signs

No single metric tells the full story. See the FRA:74C stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.

CROSSJECT Business Description

Other Exchanges ALCJ:France74C:Germany
Address 60L avenue du 14 Juillet, Chenôve, FRA, 21300
CROSSJECT manufactures and markets needle-free drug self-injection system.
41GF Score

Get the complete analysis for FRA:74C

Total Operating Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

€1.66
Price
€1.11
GF Value